Analyser av BICO Group

BICO's Q2 marked a second consecutive quarter of positive organic growth, alongside a return to EBITDA profitability as cost savings began t...

BICO's Q2 report slightly missed on sales as project-based softness persisted, but a sharp margin recovery, and positive EBITDA offers an ea...

BICO delivered 11% organic growth in Q1 2026, although coming in slighty behind our estimates in absolute terms.

The Q1 report came in slightly below our projections showing organic growth of 11% in local currencies, an encouraging signal, however FX he...

BICO’s Q4 report broadly aligned with our estimates, showing slightly negative organic growth and adjusted EBITDA profitability of 12.

BICO's Q4 report aligned closely with our projections and does not prompt any meaningful change to our view of the case.

Redeye provides a preview of its estimates ahead of BICO’s Q4 results, scheduled for release on November 4.

Redeye updates its estimates and fair value range following BICO’s Q3 2025 report showing a return to organic growth in line with our projec...

Redeye provides its initial comments on BICO following its Q3 results, which came in above expectations overall.

Redeye provides a preview of its estimates ahead of BICO’s Q3 results, scheduled for release on November 4.

Redeye initiates coverage of BICO, a leading player in the bioconvergence space.